Ramadan is followed by a huge population in the Islamic world, leading to the importance of addressing clinical risks associated with prolonged fasting in patients with diabetes, especially when treated with SGLT2 inhibitors [17]. This evidence concerns the gene SLC5A2 and diabetes mellitus.